Breast Cancer Clinical Trial
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel.
In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b).
In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
The Escalation cohorts (Part 1) have been completed. The expansion cohorts (Part 2) are open to enrollment.
Has a histologic or cytologic diagnosis of a malignant solid tumor.
Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell lung cancer (SCLC) diagnosis; participants enrolled to Part 2b (combination therapy, dose expansion) must have either NSCLC or HR-positive/HER2-negative breast cancer.
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
Failure of at least 1 prior systemic chemotherapy including all available standard therapies for participants in the dose-escalation phase (Parts 1a and 1b).
All participants with breast cancer for subjects in the dose-expansion phase (Part 2b only) must have the following:
Locally advanced or metastatic HR-positive/HER2-negative breast cancer after failing cyclin-dependent kinase (CDK)4/6 inhibitor-based therapy.
HR-positivity and HER-2-negativity should be confirmed based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria.
All participants with non-small cell lung cancer (NSCLC) for participants in the dose-expansion phase (Part 2b only) must have R/R NSCLC after at least 1 line of therapy.
All participants with SCLC in the dose-expansion phase (Part 2a only) must have R/R SCLC from at least 1 line of therapy which includes a platinum-based therapy with or without an anti-PD-1/PD-L1 therapy.
All participants with either breast cancer or NSCLC must have the following if exposed to prior taxane-based therapy:
No history of taxane allergy (Part 1b and Part 2b only).
Disease that has relapsed or progressed at least 2 months after most recent exposure to any taxane-based therapy.
Available tumor tissue suitable for immunohistochemistry testing.
Adequate kidney, liver, and hematologic laboratory values as described in the protocol.
Untreated brain or meningeal metastases (participants with a history of metastases may be eligible based on details described in the protocol).
Grade 2 or higher peripheral neuropathy (only applies to participants who would receive taxane therapy).
Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.
Known active infection of hepatitis B, hepatitis C, or human immunodeficiency virus with exceptions as described in the protocol.
Recent history (within 6 months) of congestive heart failure (defined in the protocol), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological or surgical intervention, pericardial effusion, or pericarditis.
Any history of hypersensitivity to any ingredients of ABBV-155 will be excluded. For combination therapy only (Parts 1b and 2b), no history of serious allergic reaction to any taxane or any ingredients used in taxane formulation (e.g., cremaphor).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 40 Locations for this study
Birmingham Alabama, 35233, United States
Springdale Arkansas, 72762, United States
Orange California, 92868, United States
West Hollywood California, 90048, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06510, United States
Orlando Florida, 32804, United States
Chicago Illinois, 60611, United States
Baltimore Maryland, 21224, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Detroit Michigan, 48202, United States
New Hyde Park New York, 11042, United States
Huntersville North Carolina, 28078, United States
Cleveland Ohio, 44106, United States
Providence Rhode Island, 02903, United States
Nashville Tennessee, 37232, United States
Houston Texas, 77030, United States
San Antonio Texas, 78229, United States
Melbourne New South Wales, 3000, Australia
Edmonton Alberta, T6G 1, Canada
Toronto Ontario, M5G 2, Canada
Ramat Gan Tel-Aviv, 52656, Israel
Haifa , 31096, Israel
Kashiwa-shi Chiba, 277-8, Japan
Chuo-ku Tokyo, 104-0, Japan
Goyang Gyeonggido, 10408, Korea, Republic of
Seoul Seoul Teugbyeolsi, 03722, Korea, Republic of
Amsterdam Noord-Holland, 1066 , Netherlands
Rotterdam Zuid-Holland, 3015 , Netherlands
Maastricht , 6229 , Netherlands
Utrecht , 3584 , Netherlands
Madrid , 28040, Spain
Madrid , 28041, Spain
Taichung City , 40447, Taiwan
Tainan , 704, Taiwan
Taipei City , 100, Taiwan
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.